iShares MSCI Denmark ETF (EDEN) is heavily weighted in healthcare (about 38%), with more than 18% of the fund being invested in pharma giant Novo Nordisk
Capital Ideas Media | June 8, 2021 | SmallCapPower: We were intrigued to discover recently that a top-performing Canadian asset manager we know has invested a portion of his clients’ money into iShares MSCI Denmark ETF (EDEN).
Danish stocks have performed well over the past year, which is at least partially related to Denmark’s handling of the COVID-19 pandemic.
Last week, Denmark announced it would re-open its economy sooner than expected, as COVID infections have decreased significantly.
According to Reuters, Denmark has avoided a third wave of the COVID-19 epidemic after imposing wide lockdown measures in December, which slowed the epidemic considerably to between 500-700 daily infections from several thousands in December. Activities such as indoor dining, however, will require patrons to show proof of being given a COVID vaccination.
Would-be EDEN investors will own an ETF that is heavily weighted in healthcare (about 38%), with more than 18% of the fund being invested in pharma giant Novo Nordisk. The Demark ETF has also received top marks for its sustainable (ESG) investing.
EDEN ETF holders have realized an average annual return of about 15% over the past five years, with low relative volatility, and that momentum is expected to continue during 2021.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
 is heavily weighted in healthcare (about 38%), with more than 18% of the fund being invested in pharma giant Novo Nordisk.){kind=link}